Coming off a year in which it advanced its multi-drug clinical-stage pipeline and scored a major deal with Genentech Inc., Bothell, Wash.-based Seattle Genetics Inc. has given no indication of slowing down, as it starts 2008 with a $90 million public offering. (BioWorld Today) Read More
